BioCryst hereditary disorder drug succeeds in trial, shares jump

BioCryst Pharmaceuticals Inc's oral drug to prevent a hereditary disorder characterized by abnormal swelling was effective in reducing attacks, sending the drugmaker's shares up as much as 22 percent. The drug, if approved, will be the first oral preventive for hereditary angioedema (HAE) – a disease characterized by sudden attacks of swelling of the skin or mucous membranes, which can be disfiguring, painful and even fatal. While Shire Plc's Firazyr, Dyax Corp's Kalbitor and CSL Behring's Berinert are injected to manage attacks after they occur, BioCryst's oral preventive would directly compete with Shire's injectable Cinryze. We'd like to make Cinryze obsolete because its an IV therapy," BioCryst's Chief Medical Officer William Sheridan told Reuters.



via Health News Headlines - Yahoo News http://ift.tt/1mjZBlb